Corrigendum: Primary Hyperoxaluria Type 1 (PH1) Presenting with End-Stage Kidney Disease and Cutaneous Manifestations in Adulthood: A Case Report

Poyah, P., Bergman, J., Geldenhuys, L., Wright, G., Walsh, N. M., Hull, P., Roche, K., & West, M. L. (2021). Primary Hyperoxaluria Type 1 (PH1) Presenting with End-Stage Kidney Disease and Cutaneous Manifestations in Adulthood: A Case Report. Canadian journal of kidney health and disease, 8, 20543581211058931. https://doi.org/10.1177/20543581211058931.

In the paragraph entitled “Follow-up and Outcomes”, the correct and actual dose given was Lumasiran 3 mg/kg subcutaneously monthly for 3 months, then every 3 months. The sentence should therefore read “Lumasiran (Alnylam [Oxlumo™] Pharmaceuticals Inc, Cambridge MA, USA) 3 mg/kg subcutaneously monthly for 3 months, then every 3 months was started on a compassionate basis 11 months after presentation.”